Why the study?
Does metformin alone or in combination reduce morbidity and mortality in subjects with heart failure and type 2 diabetes compared with sulfonylurea monotherapy?
Does metformin alone or in combination reduce morbidity and mortality in subjects with heart failure and type 2 diabetes compared with sulfonylurea monotherapy?
Metformin use is associated with improved clinical outcomes (lower morbidity and mortality) in patients with concurrent heart failure and type 2 diabetes compared to sulfonylurea monotherapy.
No takes yet. Share an insight, caveat, or question.
May favor metformin over sulfonylureas in HF with T2D; hypothesis-generating pending RCT confirmation.
Eurich et al. (2005) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: